Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Preliminary approval granted for settlement of consolidated derivative litigation against CorMedix-related parties.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Preliminary approval granted for settlement of consolidated derivative litigation against CorMedix-related parties
- Final settlement hearing scheduled for September 23, 2026, before the U.S. District Court for New Jersey
- Related shareholder derivative action in New Jersey state court included in proposed settlement
- Court notices and settlement agreement attached as Exhibits 99.1 and 99.2 for settlement terms and potential shareholder implications
Item EX-99.1 · Exhibit EX-99.2
- Proposed settlement resolves derivative litigation alleging fiduciary breaches tied to DefenCath manufacturing deficiencies and delayed FDA approval
- CorMedix to implement or maintain corporate-governance reforms for at least 3.5 years
- Plaintiffs’ counsel may seek up to $3.9 million in fees and expenses, subject to court approval
- Settlement provides no shareholder cash payment and requires no admission of wrongdoing by defendants
- Court approval hearing scheduled for September 23, 2026; objections due September 2, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.